Trials / Completed
CompletedNCT01925365
Health Benefits of Whole Grain Oats in Population at Risk of Cardio-metabolic Disease
Hypocholesterolaemic and Prebiotic Effects of a Whole-grain Oat-based Breakfast Cereal in a Cardio-metabolic 'at Risk' Population
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- University of Reading · Academic / Other
- Sex
- All
- Age
- 23 Years – 64 Years
- Healthy volunteers
- Accepted
Summary
Intake of whole grain cereals has been associated with reducing the risk of hyperlipidaemia and heart disease, however the mechanisms by which oats or oat fractions exert this effect is not totally clear. Furthermore, several large epidemiological studies and a number of recent meta-analyses of nutritional interventions have reported a positive association between increased whole grain intake and reduced risk of developing a range of chronic diseases. Recognising the important role of the gut microbiota in metabolism and metabolic disease risk, we examined the impact of whole grain oats on the human gut microbiota and cardio-metabolic risk factors. The main aims of this human study is to determine the effectiveness of a low GI whole grain oats breakfast cereal compared to a high GI, refined breakfast cereal to beneficially modulate gut microbiota and its metabolic output, plasma lipids, gut satiety hormones and inflammation markers in an at risk of cardio-metabolic disease population
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | wholegrain cereals oats (WGO) | Volunteers had to consume wholegrain cereals oats (WGO)(45g/day) for six weeks followed by a four week wash out period |
| DIETARY_SUPPLEMENT | Non wholegrain cereals | Volunteers had to consume non wholegrain cereals (NWG)(45g/day) for six weeks followed by a four week wash out period. |
Timeline
- Start date
- 2009-05-01
- Primary completion
- 2009-12-01
- Completion
- 2010-05-01
- First posted
- 2013-08-19
- Last updated
- 2013-08-19
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT01925365. Inclusion in this directory is not an endorsement.